Close
FINDING CURES TOGETHER<sup>SM</sup>

AACR Applauds Presidential Nomination of Norman (“Ned”) Sharpless, MD, as Director of the National Cancer Institute

AACR expresses appreciation to Doug Lowy, MD, for his stewardship of the NCI since April 2015
6/11/2017

PHILADELPHIA — The American Association for Cancer Research, the world’s first and largest cancer research organization, congratulates Ned Sharpless, MD, on his nomination by President Donald Trump to serve as the 15th director of the National Cancer Institute (NCI).

“Dr. Sharpless brings impressive qualifications to this extremely important position, including his background as a top-tier physician-scientist and his previous positions at the University of North Carolina (UNC), including his current role as director of the prestigious UNC Lineberger Comprehensive Cancer Center," said AACR President Michael A. Caligiuri, MD, director, The Ohio State University Comprehensive Cancer Center and chief executive officer of the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.  "His enthusiasm for innovative scientific methods and ideas, as well as his appreciation for the value and importance of basic research to advancing translational discoveries, will allow the NCI to continue leading the way in programs aimed at preventing disease, improving health and reducing suffering from cancer, while also helping to maintain America’s edge in the life sciences."

Dr. Sharpless will succeed Doug Lowy, MD, who has served as acting director of the NCI since the spring of 2015.  During his two years as acting director, Dr. Lowy provided critical leadership to advance the National Cancer Moonshot Initiative that Vice President Biden spearheaded during the final year of the Obama Administration.

“The entire cancer research and patient care community owes Dr. Lowy a tremendous amount of gratitude over the past two years for his extraordinary dedication and outstanding commitment to reducing cancer incidence, morbidity, and mortality,” said Margaret Foti, PhD, MD (hc), chief executive officer of the AACR. “Last night’s appointment by President Trump to select Dr. Sharpless as NCI’s next director ensures a continuity in leadership and management at the NCI that is especially needed during this historic era of unprecedented scientific opportunities that are before us. Therefore, we are absolutely thrilled about Dr. Sharpless’ appointment as we greatly respect and value his expertise and leadership in the cancer research community, and the AACR truly looks forward to working with Dr. Sharpless in the months and years to come.”